Related Experiment Video

Updated: Apr 30, 2026

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
09:44

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

9.0K

Therapeutics based on stop codon readthrough

Kim M Keeling1, Xiaojiao Xue, Gwen Gunn

  • 1Department of Microbiology and Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, Alabama 35294; email: kkeeling@uab.edu , xjxue@uab.edu , gwengunn@uab.edu , dbedwell@uab.edu.

Annual Review of Genomics and Human Genetics
|April 30, 2014
PubMed

Insights

Nonsense suppression therapy aims to restore protein function by overcoming premature stop signals in genetic diseases. This review explores current therapeutic strategies and challenges for clinical application.

Area of Science:

  • Genetics
  • Molecular Biology
  • Pharmacology

Background:

  • Genetic diseases often result from premature termination codons (PTCs) leading to non-functional proteins.
  • Nonsense mutations are a significant cause of inherited disorders, necessitating targeted therapeutic interventions.

Purpose of the Study:

  • To review the current landscape of nonsense suppression therapy for genetic disorders caused by PTCs.
  • To elucidate the mechanisms and therapeutic approaches for PTC suppression.
  • To identify barriers to clinical application and propose solutions.

Main Methods:

  • Review of existing literature on PTC suppression mechanisms and therapeutic strategies.
  • Analysis of approaches including readthrough drugs, suppressor tRNAs, PTC pseudouridylation, and NMD inhibition.
  • Discussion of clinical translation challenges and potential future directions.

Main Results:

  • Several therapeutic strategies are under development to suppress PTCs, including small molecules and genetic approaches.
  • Understanding the mechanisms of PTC suppression is crucial for developing effective therapies.
  • Barriers to clinical application include delivery, specificity, and off-target effects.

Conclusions:

  • Nonsense suppression therapy holds significant promise for treating genetic diseases caused by nonsense mutations.
  • Overcoming current clinical barriers is essential for realizing the therapeutic potential of PTC suppression.
  • Further research and development are needed to advance these therapies toward widespread clinical use.
Keywords:
nonsense mutationnonsense suppression therapypremature termination codonsreadthrough

More Related Videos

Identifying Amino Acid Overproducers Using Rare-Codon-Rich Markers10:41

Identifying Amino Acid Overproducers Using Rare-Codon-Rich Markers

Published on: June 24, 2019

7.9K
Removal of an Internal Translational Start Site from mRNA While Retaining Expression of the Full-Length Protein05:48

Removal of an Internal Translational Start Site from mRNA While Retaining Expression of the Full-Length Protein

Published on: March 16, 2022

2.0K

Related Concept Videos

Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
9.4K
Leaky Scanning02:28

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
4.5K
Translation01:31

Translation

Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
16.8K
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
133.6K
Improving Translational Accuracy02:07

Improving Translational Accuracy

Base complementarity between the three base pairs of mRNA codon and the tRNA anticodon is not a failsafe mechanism. Inaccuracies can range from a single mismatch to no correct base pairing at all. The free energy difference between the correct and nearly correct base pairs can be as small as 3 kcal/ mol. With complementarity being the only proofreading step, the estimated error frequency would be one wrong amino acid in every 100 amino acids incorporated. However, error frequencies observed in...
11.6K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121